Exact Sciences Reports 16% Revenue Growth to $811.1 Million in Q2 2025

Exact Sciences Corporation reported significant financial performance in its latest quarterly filing, with total revenue reaching $811.1 million for the three months ended June 30, 2025, a 16% increase from $699.3 million in the same period last year. For the first half of 2025, revenue totaled $1.52 billion, up from $1.34 billion in the prior year. The company achieved a gross profit of $562.5 million for the second quarter, compared to $488.3 million in the previous year, reflecting improved operational efficiency despite a net loss of $1.2 million, a notable reduction from a loss of $15.8 million in Q2 2024.

The company’s operational metrics showed a positive trend, particularly in its screening and precision oncology segments. Screening revenue, primarily from its Cologuard and PreventionGenetics tests, increased to $628.5 million in Q2 2025, up from $531.6 million a year earlier. Precision oncology revenue also rose to $182.6 million, compared to $167.7 million in the same quarter of 2024. The growth in revenue was attributed to increased adoption of its testing services, with a notable rise in customer counts and engagement metrics.

Exact Sciences has also made strategic moves to enhance its market position. The company entered into a collaboration and license agreement with Freenome Holdings, Inc. to develop and commercialize blood-based screening products for colorectal cancer, committing to an upfront payment of $75 million and potential milestone payments totaling up to $700 million. Additionally, the company is restructuring certain support functions as part of a multi-year productivity plan aimed at improving operational efficiency and reducing general and administrative costs by approximately $30 million over the next two years.

On the operational front, Exact Sciences reported a total employee headcount of approximately 3,000 as of June 30, 2025, reflecting a slight increase from the previous year. The company’s cash and cash equivalents stood at $657.1 million, up from $600.9 million at the end of 2024, providing a solid liquidity position to support ongoing investments and operational needs. The company also reported a decrease in total liabilities to $3.33 billion from $3.53 billion at the end of 2024, indicating improved financial health.

Looking ahead, Exact Sciences remains optimistic about its growth trajectory, driven by the expansion of its product offerings and strategic partnerships. The company anticipates continued revenue growth as it leverages its innovative testing solutions and enhances its market presence. The management has indicated that the restructuring initiatives and collaborations are expected to yield significant benefits in the coming quarters, positioning the company for sustainable growth in the competitive healthcare landscape.